YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Bacillus coagulans OFR17 Strain Resistant to Rifampicin and Ofloxacin

리팜피신과 오플록사신에 내성인 Bacillus coagulans OFR17 균주

  • Published : 1997.08.01
Download PDF
⟨ Previous Next ⟩

Abstract

The preparation of Bacillus coagulans is used as a therapeutics for human intestinal disorders. However, the bacterium in the preparation is very susceptible to rifampic in and fluoroquinolones. When the preparation is taken with rifampicin or fluoroquinolones, its therapeutic effect can not be expected. So B. coagulans RFR17 resistant to rifampicin was obtained by treating the parent B. coagulans with N-methyl-N'-nitro-N-nitrosoguanidine. B. coagulans OFR17 was produced by serial passage of B. coagulans RFR17 on agar with 2-fold minimal inhibitory concentration of ofloxacin or ciprofloxacin. B. coagulans OFR17 was resistant to fluoroquinolones up to 16~64 fold higher than that for the original strain. B. coagulans OFR17 also exhibited identical characteristics with the parent strain when they were tested for lactic acid production and growth inhibition of E. coli MB4-01 and Shigella sonnei MB4-10411. From in vitro test, it was also identified that rifampicin and ofloxacin are not inactivated by certain factors of B. coagulans OFR17. Conclusively, B. coagulans OFR17 can be regarded as a promising strain which can be developed as the preparation for the treatment of the intestinal disorders of the tuberculosis patients under rifampicin and ofloxacin therapy.

Keywords

References

  1. Thesis. Seoul National. Univ. Development of Clostridium butyricum resistant to rifampicin. Choi, S.S.
  2. Kor. J. Microbiol. v.27 Development of Lactobacillus sporogenes resistant to rifampicin. an antituberculosis agent Kim, H.S.;Choi, S.S.;Choi, E.C.;Kim, B.K.;Lee, J.C.;Kim, T.H.
  3. Lancet v.1 Lactobacillus preparation for use with antibiotics Ⅰ-Ⅱ-Ⅲ Gordon, D.;Macrae, J.;Wheater, D.M.
  4. Yakhak Hoeji v.37 Development of Streptococcus faecalis strains resistant to rifampicin Choi, E.C.;Kim, S.H.;Kwon, A.R.;Lee, M.J.;Oh, J.J.;Kim, B.K.
  5. Antimicrob. Agents Chemother v.34 Comparative in vitro activities of 20 fluoroquinolones against Mycobacterium leprae Frantz, S.G.;White, K.E.
  6. Antimicrob. Agents Chemother v.36 Activities of various quinolone antibiotics Mycobacterium leprae in infected mice Gelber, R.H.;Iranmanesh, A.;Murry, L.;Siu, D.;Tsang, M.
  7. Nature v.192 Antibiotics among lactobacilli Deklerk, H.C.;Coetzee, J.N.
  8. Can. J. Microbial. v.17 Acid injury of E. coli Roth, L.A.;Keenan
  9. 약학회지 v.40 리팜피신과 오플로삭신에 내성인 Entercoccus faecalis 균주의 개발 이수화;김숙경;정영자;심미자;김병각;최응칠
  10. J. Gener. Appl. Microb. v.43 The effects of Bifidobacterium bifidum OFR9 strain resistant to antituberculosis and antile prosy agents on the fecal flora in mice Y.J. Chung;S.K. Kim;E.C. Choi
  11. Cultured Dairy Prod. J. v.20 Antibacterial activity associated with Bifidobacterium bifidum-11 Anad, S.K.;Sirnivasna, R.A.;Rao, L.K.
  12. AC. Microbios. v.37 Isolation and purification of an inhibitory protein from Lactobacillus acidophilus Metha, A.M.;Patel, K.A.;Dave, P.J.
  13. Appl. Environ. Microbiol. v.45 Detection and activity of lactacin b, a bacteriocin produced by Lactobacillus acidophilus Suaan, F.B.;Klaehammer, T.R.
  14. Nature v.211 Inhibitory effect of Lactobacillus acidophilus Tramer, J.